BOSTON, April 11, 2023 - GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging synthetic biology to expand the amino acid alphabet and deliver on the promise of protein therapeutics,...
Read More
- Nicole Paulk, an expert in gene therapy, joins GRObio’s Scientific Advisory Board (SAB) as It Advances its ProGlyTM Immunomodulation Chemistries into Gene Therapy - BOSTON, September 7, 2022 -...
Read More
BOSTON--(BUSINESS WIRE)--GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced that it will...
Read More
BOSTON--(BUSINESS WIRE)--GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the appointment of...
Read More
BOSTON--(BUSINESS WIRE)--GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the appointment of...
Read More
November 16, 2021 06:55 AM Eastern Standard Time BOSTON--(BUSINESS WIRE)--GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise...
Read More
BOSTON, November 3, 2021 – GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the closing of a Series A financing
BOSTON, Sept. 28, 2017 – GRO Biosciences Inc. today announced that the company has secured $2.1 million in a seed funding round co-led by Digitalis Ventures and Eric Schmidt’s Innovation Endeavors.
